Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Betamethasone
Drug ID BADD_D00260
Description Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties.[A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.[A192444] Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.[A192444]
Indications and Usage As a member of the corticosteroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses.[L11991,L10782,L11997] Betamethasone can be used topically in combination with a vitamin D analog such as calcipotriene to treat plaque psoriasis.[L12000] The corticosteroid is also available as an injectable suspension and can be used to manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions.[L11994]
Marketing Status approved; vet_approved
ATC Code A07EA04; C05AA05; D07AC01; D07XC01; H02AB01; R01AD06; R03BA04; S01BA06; S01CB04; S02BA07; S03BA03
DrugBank ID DB00443
KEGG ID D00244
MeSH ID D001623
PubChem ID 9782
TTD Drug ID D0CW1P
NDC Product Code 52128-166; 22552-0030; 57582-007; 64958-0012
UNII 9842X06Q6M
Synonyms Betamethasone | Flubenisolone | Betadexamethasone | Celestona | Cellestoderm | Celeston | Celestone
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 378-44-9
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vestibular disorder17.02.02.008; 04.04.02.001--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Multiple sclerosis relapse17.16.01.003--Not Available
Hypoacusis04.02.01.006--
Application site vesicles12.07.01.009; 08.02.01.009; 23.03.01.009--Not Available
Peripheral swelling02.05.04.015; 08.01.03.053--Not Available
Oesophagitis ulcerative07.04.05.003--Not Available
Emotional distress19.04.02.008--Not Available
General physical health deterioration08.01.03.018--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Contusion15.03.05.007; 24.07.06.001; 23.03.11.002; 12.01.06.001--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Skin swelling23.03.03.039--Not Available
Growth retardation15.03.05.016; 14.03.02.031; 05.03.02.007--
Affect lability19.04.01.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000709%Not Available
Haemorrhage24.07.01.002--Not Available
Muscle mass15.05.03.018--Not Available
Tendon calcification15.07.01.006--Not Available
Application site discolouration12.07.01.030; 08.02.01.030; 23.03.03.023--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Skin test negative13.06.04.002--Not Available
Embolism24.01.01.009--
Inflammation10.02.01.089; 08.01.05.007--Not Available
Lipid metabolism disorder14.08.04.003--Not Available
Mental disorder19.07.01.002--Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages